Trevi Therapeutics to Participate in Upcoming March Conferences

Core Insights - Trevi Therapeutics, Inc. is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [3][4] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company [3] - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [3] - Haduvio functions as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in cough control [3] Market Need - There are approximately 150,000 U.S. patients with IPF, with two-thirds experiencing uncontrolled chronic cough [4] - About 228,000 U.S. patients have non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough [4] - Chronic cough can lead to significant morbidity and mortality, including increased respiratory hospitalizations and a decline in quality of life [4] Refractory Chronic Cough (RCC) Insights - RCC affects around 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [5] - RCC is associated with cough reflex hypersensitivity and can severely impact patients' physical, psychological, and social well-being [5] Upcoming Conferences - Trevi will participate in the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, with a fireside chat on March 11 [2] - The company will also be present at the Access USA, Rare Disease Summit 2026 from March 17-19, 2026, with a panel session on March 18 [2]